
The U.S. Food and Drug Administration (FDA) has granted orphan-drug designation to IDEAYA Biosciences (NASDAQ:IDYA) for its drug candidate Darovasertib for the treatment of uveal melanoma.
Darovasertib in combination with Crizotinib is being evaluated in an ongoing Phase 1/2 clinical trial in patients with metastatic uveal melanoma (MUM) and in patients with GNAQ or GNA11 mutant solid tumors.